polio sabin suspension oral
glaxosmithkline biologicals s.a. - poliovirus types 1, poliovirus types 3 - suspension oral - not less than-106ccid50/dose+ not less than-105.8ccid50/dose
polio sabin suspension oral
glaxosmithkline biologicals s.a. - poliovirus types 1, poliovirus types 3 - suspension oral - not less than-106ccid50/dose+ not less than-105.8ccid50/dose
priorix powder lyophilized and solvent for solution for injection
glaxosmithkline biologicals s.a. - live attenuated measles virus(schwarz strain), live attenuated mumps virus(rit 4385 strain), live attenuated rubella virus(wistar ra 27/3 strain) - powder lyophilized and solvent for solution for injection - not less than 103.0ccid50/dose+ not less than 103.7ccid50/dose+ not less than 103.0ccid50/dose
priorix powder lyophilized and solvent for solution for injection
glaxosmithkline biologicals s.a. - live attenuated measles virus(schwarz strain), live attenuated mumps virus(rit 4385 strain), live attenuated rubella virus(wistar ra 27/3 strain) - powder lyophilized and solvent for solution for injection - not less than 103.0ccid50/dose+ not less than 103.7ccid50/dose+ not less than 103.0ccid50/dose
priorix-tetra
glaxosmithkline pte ltd - live attenuated measles virus (schwarz strain); live attenuated mumps virus (rit4385 strain); live attenuated rubella virus (wistar ra 27/3 strain); live attenuated varicella virus (oka strain) - injection, powder, lyophilized, for solution - ≥ 10 3.0 ccid50 /dose - live attenuated measles virus (schwarz strain) ≥ 10³ ccid50/dose; live attenuated mumps virus (rit4385 strain) ≥ 10⁴·⁴ ccid50/dose; live attenuated rubella virus (wistar ra 27/3 strain) ≥ 10³ ccid50/dose; live attenuated varicella virus (oka strain) ≥ 10³·³ pfu/dose
ipv-boostrix suspension for injection in pre-filled syringe
glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 2.5 µg pertussis toxoid 8 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 8 µg tetanus toxoid - vaccines
pandemrix
glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.
prepandrix
glaxosmithkline biologicals s.a. - a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with h5n1 subtype strains.prepandrix should be used in accordance with official guidance.
infanrix suspenion for injection
glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin - suspenion for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose
engerix b adult suspension for injection
glaxosmithkline biologicals s.a. - hepatitis b surface antigene (recombinant dna) - suspension for injection - 20mcg/ml